The research team will conduct clinical trials to evaluate
a novel immunotherapy treatment which combines a molecule expressed by cancer cells with a modified live form of the bacteria Listeria monocytogenes.
Not exact matches
Combined
treatment with two cancer
immunotherapy drugs — one a
novel immune modulator and one that focuses and activates the antitumor immune response — significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.
About VentiRx VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of
novel Toll - like receptor 8 (TLR8)
immunotherapies for the
treatment of cancer, respiratory and inflammatory diseases.
Many of these
novel cancer
immunotherapy approaches, which originated from basic science research in CCIR laboratories, are now being explored as new
treatment modalities in patients, with a significant number advancing through clinical trials towards FDA approval.
Immunotherapy is being investigated as a
novel treatment for cancer.
My experience spans two decades of translating
novel immunotherapies into clinical application for the
treatment of melanoma.
Research in the Leukemia Program spans from direction of clinical trials to basic molecular studies of leukemia biology,
immunotherapy and development of
novel agents, and to mitigating the late effects of
treatment in long - term survivors.
Rutgers Cancer Institute along with its partner RWJBarnabas Health, offers patients access to the most advanced
treatment options including clinical trials and
novel therapeutics such as precision medicine, and
immunotherapy — many of which are not available at other facilities across the state.
Led by Christiana Davis, MD, (in collaboration with Dr. Peter Gabriel, Chief Oncology Informatics Officer and Abigail Doucette, MPH, Research Registry Program Manager), the Thoracic TCE has established project - based databases to track the demographics and response status of patients to immune - oncology
treatments, as well as acquired resistance to standard therapies and
novel targeted
immunotherapies.
Patients will be able to receive the Hutch's
novel immunotherapies for cancer at roughly double the capacity that existed before the 9,222 - square - foot clinic opened, and intensive monitoring will enable researchers to better understand why some patients respond, where others do not, and to achieve the goal of developing the best curative approach to
treatment for each individual patient.
Areas of focus include: understanding how tumour - reactive T cells and B cells promote patient survival in cancer; defining the effects of standard
treatments on tumor immunity; and using genomic approaches to identify
novel tumour mutations that can serve as target antigens for
immunotherapy.
NasVax and Ramot Announce Licensing Agreement on
Novel Immunotherapies for
Treatment of Alzheimer's Disease
«Immune checkpoint inhibitors, including PD - 1 and PD - L1 inhibitors, have provided meaningful clinical benefits for patients with cancer; however,
novel immunotherapy combination
treatments are needed to improve efficacy with limited additive toxicity,» said Aung Naing, MD, FACP, associate professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.